HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Abstract
A low response to clopidogrel has been associated with an increased risk of stent thrombosis. However, the definition of a nonresponse to clopidogrel remains controversial, and different tests have been used to assess the clopidogrel response. The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention. A total of 598 consecutive patients with non-ST-elevation acute coronary syndrome undergoing coronary stenting were prospectively included. They received 600 mg of clopidogrel >or=12 hours before percutaneous coronary intervention. Acute or subacute definite or probable stent thrombosis occurred in 11 patients (1.8%). These patients had significantly greater ADP-Ag compared to patients free of stent thrombosis (68 +/- 14% vs 56 +/- 19%, p = 0.002) but only a trend toward a greater Platelet Reactivity Index of vasodilator-stimulated phosphoprotein (62 +/- 14% vs 53 +/- 23%, p = 0.19). The construction of receiver operating characteristic curves to examine the most predictive value of ADP-Ag for stent thrombosis gave a threshold of ADP-Ag of >67% to identify low responders. These patients were at a greater risk of stent thrombosis than the clopidogrel responders (4.3% vs 0.8%, odds ratio 5.8, 95% confidence interval 1.9 to 24.6, p = 0.003). In conclusion, in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention, ADP-Ag is a good parameter to identify clopidogrel nonresponders who are at increased risk of stent thrombosis, with a cutoff value of ADP-Ag of >67%.
AuthorsThomas Cuisset, Corinne Frere, Jacques Quilici, Bénédicte Gaborit, Christel Castelli, Raphael Poyet, Laurent Bali, Pierre-Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet
JournalThe American journal of cardiology (Am J Cardiol) Vol. 104 Issue 8 Pg. 1078-82 (Oct 15 2009) ISSN: 1879-1913 [Electronic] United States
PMID19801028 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Proteins
  • Cell Adhesion Molecules
  • Microfilament Proteins
  • Phosphoproteins
  • Platelet Aggregation Inhibitors
  • vasodilator-stimulated phosphoprotein
  • Adenosine Diphosphate
  • Clopidogrel
  • Ticlopidine
Topics
  • Acute Coronary Syndrome (blood, therapy)
  • Adenosine Diphosphate (therapeutic use)
  • Aged
  • Angioplasty, Balloon, Coronary (methods)
  • Blood Proteins
  • Cell Adhesion Molecules (blood)
  • Clopidogrel
  • Coronary Thrombosis (blood, etiology, prevention & control)
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Microfilament Proteins (blood)
  • Middle Aged
  • Odds Ratio
  • Phosphoproteins (blood)
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Prognosis
  • Prospective Studies
  • Prosthesis Failure
  • ROC Curve
  • Risk Factors
  • Stents
  • Ticlopidine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: